Finally, we further predicted the prognostic value of CEMIP in BC patients by taking the stage, age, molecular subtype, ER/PR/HER2 status, TNM status, and TP53 mutation status into consideration in addition to the expression level of CEMIP using the Cox Proportional Hazards model based on TCGA cohorts. The gene discussed is CEMIP; the disease is breast cancer.